The potential of DNA vaccination against tumor-associated antigens for antitumor therapy

被引:44
|
作者
Haupt, K
Roggendorf, M
Mann, K
机构
[1] Univ Essen Gesamthsch, Dept Internal Med, Div Clin Chem, D-45122 Essen, Germany
[2] Univ Essen Gesamthsch, Inst Virol, D-45122 Essen, Germany
[3] Univ Essen Gesamthsch, Dept Internal Med, Div Endocrinol, D-45122 Essen, Germany
关键词
DNA vaccination; immunotherapy; tumor; immune response;
D O I
10.1177/153537020222700403
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Conventional treatment approaches for malignant tumors are highly invasive and sometimes have only a palliative effect. Therefore, there is an increasing demand to develop novel, more efficient treatment options. Increased efforts have been made to apply immunomodulatory strategies in antitumor treatment. In recent years, immunizations with naked plasmid DNA encoding tumor-associated antigens have revealed a number of advantages. By DNA vaccination, antigen-specific cellular as well as humoral immune reponses can be generated. The induction of specific immune responses directed against antigens expressed in tumor cells and displayed e.g., by MHC class I complexes can inhibit tumor growth and lead to tumor rejection. The improvement of vaccine efficacy has become a critical goal in the development of DNA vaccination as antitumor therapy. The use of different DNA delivery techniques and coadministration of adjuvants including cytokine genes may influence the pattern of specific immune responses induced. This brief review describes recent developments to optimize DNA vaccination against tumor-associated antigens. The prerequisite for a successful antitumor vaccination is breaking tolerance to tumor-associated antigens, which represent "self-antigens." Currently, immunization with xenogeneic DNA to induce immune responses against self-molecules is under intensive investigation. Tumor cells can develop immune escape mechanisms by generation of antigen loss variants, therefore, it may be necessary that DNA vaccines contain more than one tumor antigen. Polyimmunization with a mixture of tumor-associated antigen genes may have a synergistic effect in tumor treatment. The identification of tumor antigens that may serve as targets for DNA immunization has proceeded rapidly. Preclinical studies in animal models are promising that DNA immunization is a potent strategy for mediating antitumor effects in vivo. Thus, DNA vaccines may offer a novel treatment for tumor patients. DNA vaccines may also be useful in the prevention of tumors with genetic predisposition. By DNA vaccination preventing infections, the development of viral-induced tumors may be avoided.
引用
收藏
页码:227 / 237
页数:11
相关论文
共 50 条
  • [31] Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).
    Ragone, Concetta
    Manolio, Carmen
    Cavalluzzo, Beatrice
    Mauriello, Angela
    Tornesello, Maria Lina
    Buonaguro, Franco M.
    Castiglione, Filippo
    Vitagliano, Luigi
    Iaccarino, Emanuela
    Ruvo, Menotti
    Tagliamonte, Maria
    Buonaguro, Luigi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)
  • [32] Tumor-associated Carbohydrate Antigens: Sialyl Lea and T/Tn Antigens in Canine Mammary Tumors
    Nowak, M.
    Madej, J.
    Dzicgiel, P.
    Lopljszynski, W.
    Rodo, A.
    Ugorski, M.
    VETERINARY PATHOLOGY, 2009, 46 (02) : 222 - 226
  • [33] Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice
    Fabian, Kellsye Paula L.
    Chi-Sabins, Nina
    Taylor, Jennifer L.
    Fecek, Ronald
    Weinstein, Aliyah
    Storkus, Walter J.
    ONCOIMMUNOLOGY, 2017, 6 (03):
  • [34] Gut microbiota and tumor-associated macrophages: potential in tumor diagnosis and treatment
    Zhou, Dongqin
    Li, Yongsheng
    GUT MICROBES, 2023, 15 (02)
  • [35] Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy
    Schweer, David
    McAtee, Annabel
    Neupane, Khaga
    Richards, Christopher
    Ueland, Frederick
    Kolesar, Jill
    CANCERS, 2022, 14 (09)
  • [36] COMPARISON OF 15 MONOCLONAL-ANTIBODIES AGAINST TUMOR-ASSOCIATED ANTIGENS OF TRANSITIONAL CELL-CARCINOMA OF THE HUMAN BLADDER
    HULAND, E
    MEIER, T
    BARICORDI, O
    FRADET, Y
    GROSSMAN, HB
    HODGES, GM
    MESSING, EM
    SCHMITZDRAEGER, BJ
    JOURNAL OF UROLOGY, 1991, 146 (06) : 1631 - 1636
  • [37] Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy
    Lin, Xiaojie
    Fang, Yan
    Jin, Xuechao
    Zhang, Mingming
    Shi, Kai
    ACS APPLIED BIO MATERIALS, 2021, 4 (08) : 5871 - 5896
  • [38] Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination
    Huang, Chung-Hsiung
    Huang, Chiung-Yi
    Ho, Hui-Min
    Lee, Ching-Hung
    Lai, Pang-Ti
    Wu, Suh-Chin
    Liu, Shih-Jen
    Huang, Ming-Hsi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [39] Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma
    Huebener, N
    Lange, B
    Lemmel, C
    Rammensee, HG
    Strandsby, A
    Wenkel, J
    Jikai, J
    Zeng, Y
    Gaedicke, G
    Lode, HN
    CANCER LETTERS, 2003, 197 (1-2) : 211 - 217
  • [40] Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer
    Diaz-Zaagoza, Mariana
    Hernandez-Avila, Ricardo
    Viedma-Rodriguez, Rubi
    Arenas-Aranda, Diego
    Ostoa-Saloma, Pedro
    ONCOLOGY REPORTS, 2015, 34 (03) : 1106 - 1114